{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 40,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines a dual-track strategy: oncology (solid tumors) and autoimmune diseases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/38",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.06,
        "y": 0.52
      },
      "kind": "list",
      "text": "Plasma cell depletion in vivo\nConcomitant decline in Immunoglobulin levels\nExploring autoimmune disease potential\nDiseases caused by pathogenic antibodies\nMyasthenia gravis, ITP, pemphigus, etc.\nSimilar market potential to FcRn inhibitors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77606ac2-81e7-45a4-ab83-6ea8dec0771e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "Proof-of-concept achieved with NKp30xBCMA and NKp30xCD20\nFocus on solid tumors, specifically, immune resistant tumors (prostate, ovarian, etc.)\nAntigens with relatively low density?\nCTX-8573\n2020 goal: advance an NKp30xTAA to clinical candidate nomination",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd18becd-4f36-46b3-ae92-c98671d95922",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.02,
        "y": 0.08
      },
      "kind": "title",
      "text": "NKp30 Platform: Strategy and Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb998a6d-13fc-465b-b243-2387e06d9b3f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}